Thermo Fisher Scientific IncTMO
▲ PositiveTechnologyCapitalrelevance
Thermo Fisher launched the Gibco CHO-K1 Catalog Panel, a new cGMP-ready media portfolio yielding up to 73% higher antibody titer for biologics production.
Impact on assets 1
Biotech & Genomic Medicine
Thermo Fisher Scientific IncTheme Impact 3
Off-coverage companies
Related news
Congo - Kinshasa▲
Roche Diagnostics Sends Two Molecular Testing Instruments to DRC for Ebola Testing
Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique to support Ebola testing capacity in the Democratic Republic of Congo, where an outbreak caused by Bundibugyo virus has pushed demand for testing beyond current laboratory capacity. Roche will preconfigure the Light cycler and Magna Pure instruments and train local laboratory technicians before deploying the equipment to Bunia for validation testing. The Institut National de Santé Publique will conduct local validation of the Bundibugyo virus, after which Roche anticipates further tests could be shipped and additional instruments deployed. The delivery follows Roche's June announcement that it had developed a Research Use Only molecular PCR test targeting Bundibugyo virus. As of 28 September 2026, UN Health Authority data reported 8,067 confirmed cases and 3,901 deaths, a case fatality rate of 48.4% across 60 health zones in six provinces, and the WHO has assessed the risk in the DRC as very high and confirmed the outbreak remains a public health emergency of international concern.
About megatrends
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Demand
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
Biotech & Genomic Medicine › Life-Science Tools & Sequencing ▲Demand
ROP.SW · Demand · Positive Roche Diagnostics supplies molecular testing instruments and PCR tests to support Ebola testing in the DRC, expanding demand for its diagnostics products
Netherlands
Norway▲
QIAGEN Launches AI Bioinformatics Tools for Research and Drug Discovery
QIAGEN N.V. announced new artificial intelligence capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis, and the new QIAGEN Discovery Platform, which extends these capabilities into automated drug discovery workflows. The new offerings build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights, whose bioinformatics solutions are used by around 150,000 users. The global market for AI in bioinformatics is projected to more than double from about $12 billion in 2026 to more than $25 billion by 2031, according to Mordor Intelligence. At the University of Bergen in Norway, researchers tested IPA Investigator using complex datasets that deliberately introduced misleading sample comparisons, and Dr. Simona Chera, Professor at the University of Bergen, said the tool identified the problem, cautioned against overinterpreting the results and suggested a better experimental design.
About megatrends
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Technology
Biotech & Genomic Medicine › Life-Science Tools & Sequencing ▲Technology
QGEN · Technology · Positive QIAGEN launched new AI bioinformatics tools (IPA Investigator and QIAGEN Discovery Platform) for research and drug discovery.
QIAGEN Digital Insights · Technology · Positive QIAGEN Digital Insights' 25-year biomedical knowledge base underpins the newly launched AI tools, extending its capabilities into automated drug discovery.
United States▲
NeoGenomics Guides to About US$209 Million Q3 2026 Revenue, Names Warren Stone CEO
NeoGenomics, Inc. issued preliminary third-quarter 2026 revenue guidance of about US$209 million with very strong next-generation sequencing growth and outlined plans to increase its full-year revenue guidance. The company also amended its bylaws to expand its Board to up to eleven directors. In a planned leadership transition, President and COO Warren Stone will become CEO and join the Board in January 2027, while current CEO Tony Zook moves to Executive Chair and the Board refreshes its independent leadership. The stronger revenue outlook, particularly in NGS, supports the near-term revenue catalyst but does not materially change the central risk that high fixed costs and heavy investment could weigh on margins if volumes soften or funding pressures persist. NeoGenomics' narrative projects $997.4 million revenue and $64.1 million earnings by 2029, with a $19.72 fair value estimate.
About megatrends
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Demand
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
Biotech & Genomic Medicine › Life-Science Tools & Sequencing ▲Demand
NEO · Capital · Positive Preliminary Q3 2026 revenue guidance of ~US$209M with very strong NGS growth and plans to raise full-year guidance
GermanyUnited States▲
Bruker timsTOF Study Maps 179,000 Human Plasma Proteoforms
Bruker Corporation announced a seminal bioRxiv preprint describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution, conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. By combining intact protein fractionation with diaPASEF mass spectrometry on Bruker timsTOF mass spectrometry systems, the researchers detected 5,077 plasma protein groups across 179,049 distinct proteoforms, with a high-confidence map comprising 44,083 proteoforms and a median of eleven proteoforms per protein. The study indicates that canonical proteins account only for a fraction of protein diversity in the blood stream and may constitute less than half of total protein content, and the workflow did not use nanoparticle-based enrichment. Dr. Markus Ralser, Einstein Professor of Biochemistry and Head of the Institute of Biochemistry at Charité – Universitätsmedizin Berlin, said the first draft of the plasma proteoform atlas shows that proteoforms are not rare exceptions but a defining feature of plasma biology. The preprint, titled "A draft atlas of the human plasma proteome at isoform resolution," was posted on September 28, 2026, and the draft isoform atlas is intended as a starting point for future proteoform in-depth studies across individuals, physiological states and diseases.
About megatrends
Biotech & Genomic Medicine › Life-Science Tools & Sequencing ▲Technology
BRKR · Technology · Positive Bruker's timsTOF mass spectrometry systems enabled a seminal plasma proteoform atlas study, showcasing its technology's capability.
United States▲
Illumina Shares Jump 7.7% as Analysts Lift Price Targets
Illumina shares jumped 7.7% in the afternoon session after Wall Street analysts raised their price targets on the genomics company, citing expected improvement in clinical sales and new catalysts. Analysts also pointed to growing investor interest in gene-sequencing technology as foundational infrastructure for artificial intelligence applications, according to TipRanks. The stock closed the day at $293.84, up 7.6% from the previous close, and has now gained 119% since the beginning of the year, setting a new 52-week high. The move was notable but not extreme for Illumina, which has seen 17 swings greater than 5% over the past year. The largest of those came 11 months ago, when the stock gained 22.4% after the company reported third-quarter 2025 results that beat profit expectations and raised its full-year guidance.
About megatrends
Biotech & Genomic Medicine › Life-Science Tools & Sequencing ▲Demand
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Demand
ChinaAutobio Diagnostics first-half revenue and net profit both declined; company says full-year overseas sales target of 600 million yuan faces considerable pressure
Autobio Diagnostics held its 2026 first-half results briefing on September 30, attended by four senior executives including Chairman Miao Yongjun and Vice President and Board Secretary Fang Ruikuan. In the first half of 2026, the company achieved total operating revenue of 2.058 billion yuan, down 0.12 percent year on year; net profit attributable to shareholders of 497 million yuan, down 12.94 percent; non-GAAP net profit of 493 million yuan, down 9.73 percent; and net cash flow from operating activities of 216 million yuan, down 47.38 percent. In response to an investor question about whether the overseas revenue target of 600 million yuan set at the beginning of the year can be met, the company said it has not adjusted the overseas sales target for now, and that meeting it faces considerable pressure. In the first half, overseas business revenue was 220 million yuan, up 40.13 percent year on year. For full-year 2025, overseas business revenue was 384 million yuan, up 34.96 percent, with products covering more than 120 countries and regions worldwide. The company said that as the share of sales from its own products increases, gross margin should rise. It also said the assembly line business, namely biochemistry and immunoassay, remains the most important growth driver at present, while microbiology and quality control products are growing rapidly with relatively large scale and are gradually contributing more to profit. It will take some time for tandem mass spectrometry, sequencing, and molecular businesses to make a contribution.
About megatrends
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▼Demand
Biotech & Genomic Medicine › Diagnostics & Precision Testing Demand
Biotech & Genomic Medicine › Life-Science Tools & Sequencing Demand
603658.CG · Capital · Negative H1 2026 revenue fell 0.12% and net profit dropped 12.94% year on year, with operating cash flow down 47.38%.
603658.CG · Demand · Negative Company says the full-year overseas sales target of 600 million yuan faces considerable pressure, with H1 overseas revenue of 220 million yuan.